Breakthrough Asthma and COPD Drug Emerges After 50 Years
Originally Published 1 year ago — by ScienceAlert
A new study published in The Lancet Respiratory Medicine reveals that benralizumab, a monoclonal antibody, may be a breakthrough treatment for asthma and COPD flare-ups, offering a safer alternative to steroids like prednisolone. The trial showed that benralizumab significantly reduced treatment failure rates and improved patient outcomes, with fewer side effects compared to steroids. While benralizumab is already used for long-term asthma management, further phase 3 trials are needed to approve its use during flare-ups.